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Abstract
Microfluidic synthesis of nanoparticles (NPs) can enhance the controllability and reproducibility
in physicochemical properties of NPs compared to bulk synthesis methods. However, applications
of microfluidic synthesis are typically limited to in vitro studies due to low production rates.
Herein, we report the parallelization of NP synthesis by 3D hydrodynamic flow focusing (HFF)
using a multilayer microfluidic system to enhance the production rate without losing the
advantages of reproducibility, controllability, and robustness. Using parallel 3D HFF, polymeric
poly(lactide-co-glycolide)-b-polyethyleneglycol (PLGA-PEG) NPs with sizes tunable in the range
of 13–150 nm could be synthesized reproducibly with high production rate. As a proof of concept,
we used this system to perform in vivo pharmacokinetic and biodistribution study of small (20 nm
diameter) PLGA-PEG NPs that are otherwise difficult to synthesize. Microfluidic parallelization
thus enables synthesis of NPs with tunable properties with production rates suitable for both in
vitro and in vivo studies.
Keywords
Nanoparticles; Nanoprecipitation; 3D flow focusing; Microfluidics; Block copolymers
© 2013 Published by Elsevier Inc.
*Corresponding authors: ofarokhzad@zeus.bwh.harvard.edu (O.C. Farokhzad), karnik@mit.edu (R. Karnik).
Conflict of Interest Statements: In compliance with the Brigham and Women’s Hospital and Harvard Medical School institutional
guidelines, O.C.F. discloses his financial interest in BIND Biosciences, Selecta Biosciences, and Blend Therapeutics, three
biotechnology companies developing nanoparticle technologies for medical applications. BIND, Selecta, and Blend did not support
the aforementioned research, and currently these companies have no rights to any technology or intellectual property developed as part
of this research. In compliance with MIT institutional guidelines, R.L. discloses his financial interest in BIND Biosciences, Selecta
Biosciences, Blend Therapeutics, and Kala, four biotechnology companies developing nanoparticle technologies for medical
applications. BIND, Selecta, Blend, and Kala did not support the aforementioned research, and currently these companies have no
rights to any technology or intellectual property developed as part of this research.
NIH Public Access
Author Manuscript
Nanomedicine. Author manuscript; available in PMC 2015 February 01.
Published in final edited form as:
Nanomedicine. 2014 February ; 10(2): 401–409. doi:10.1016/j.nano.2013.08.003.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Introduction
Polymeric nanoparticles (NPs) have shown great promise as nanocarriers for drug
delivery.1–3 NPs made of poly(lactide-co-glycolide)-b-polyethyleneglycol (PLGA-PEG)
block copolymers are particularly appealing as nanomedicines because they are
biodegradable and biocompatible, have the ability to incorporate chemical moieties
including drug molecules and targeting agents, and can controllably release their payload.4–6
Indeed, targeted PLGA-PEG NPs for prostate cancer therapy have successfully completed
Phase I clinical trials and are poised to impact human health.7
However, the translation of NPs to the clinic faces several challenges, with the majority of
the NPs not making it beyond the proof-of-concept stage.8,9 Major issues include the
extensive in vitro and in vivo screening and optimization required, and the batch-to-batch
variability in manufacture of NPs. While polymeric NPs are typically synthesized in bulk by
the nanoprecitipation/solvent exchange method or by emulsification using surfactants,
microfluidic platforms offer reaction environments that are precisely controlled at the
microscale. As a result, microfluidic platforms have been recently adopted for the synthesis
of NPs in a more controllable and reproducible manner.9–12 Microfluidic platforms also
allow systematic tuning of the biophysicochemical properties of NPs, facilitating their
screening and optimization.8,9,13–16 We have demonstrated the controlled synthesis of
PLGA-PEG NPs by rapid and tunable mixing in microfluidic platforms known as 2D
hydrodynamic flow focusing (HFF) and 3D HFF.13,17 3D HFF isolates the precipitating
polymers from microchannel walls and eliminates microchannel clogging, which has
enabled reproducible synthesis of monodisperse NPs with tunable sizes from 30–230 nm.
Synthesis of lipid NPs using rapid mixing in microfluidic channels by microvortices and
herringbone microstructures has also been reported.18–20
Despite these advances, the role of microfluidic platforms in the development of drug
delivery systems faces some challenges. While in vitro studies require small amounts of NPs
(e.g., ~50 μg/well), subsequent in vivo studies require significantly larger amounts (e.g., ~5
mg/mouse). Mixers that are suitable for larger-scale synthesis18,21 are not well-suited for
creating a library of NPs for in vitro screening. In devices such as 3D HFF that are well-
suited for in vitro screening of NPs, modifying the experimental procedures to increase the
yield drastically affects the physicochemical properties of NPs. For example, changing the
platform’s architecture to tolerate higher internal pressure affects the mixing time and the
physicochemical properties of the NPs. Therefore, parallelization of the microchannels is a
promising way to meet the NP production yields required for in vivo studies; such parallel
process approaches have been studied for emulsion droplet generation22–27 and in the
chemical engineering industry.28
Herein, we report parallel synthesis of NPs using a multilayer microfluidic system to
enhance the production yield without losing the advantages of reproducibility,
controllability, and robustness of 3D HFF. The relevance of this novel microfluidic design
for the development of PLGA-PEG NPs was assessed by synthesizing NPs in the range of
13–150 nm with high production rates. We show that NPs produced at high production rates
have identical properties as those prepared with single stream channels. Finally, as a proof
of concept, we performed in vivo pharmacokinetic (PK) and biodistribution study using
PLGA-PEG NPs rapidly synthesized by the parallel 3D HFF. This parallel microfluidic
system extends the range of applications of HFF for controlled synthesis of NPs with
tunable properties from in vitro to in vivo studies.
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Methods
Fabrication of multilayer poly(dimethylsiloxane) (PDMS) microfluidic device
Multilayer 3D HFF microfluidic device was prepared using multilayer photolithography and
multilayer soft lithography. Master molds for the bottom and upper layers were patterned in
SU-8 photoresist (SU-8 2100, MicroChem Corp., Newton, MA, USA) via conventional
photolithography. Post arrays for interconnecting holes were patterned in SU-8 on top of the
bottom layer with precise alignment using an UV aligner (MA-4, Karl Suss, Garching,
Germany). A thin PDMS (4:1 base to hardener mixture, Dow Corning, Midland, MI, USA)
membrane was spin-coated on the master mold for bottom layer with post arrays. The spin
speed (600 rpm for 30 s) was chosen to precisely control the membrane thickness to be
slightly lower than the interconnect post height. The upper PDMS microchannel was
prepared using conventional replica molding of PDMS (20:1 base to hardener mixture) from
the SU-8 master for upper layer. The upper PDMS channel was aligned under a microscope
and bonded on top of bottom PDMS membrane using oxygen plasma treatment (PDC-001,
Harrick Plasma, Ithaca, NY, USA) and then peeled off along with the bottom layer. To
assemble the final device, the multilayer PDMS channel was bonded with a slide glass via
oxygen plasma and connected to tubing.
Preparation of PLGA-PEG NPs
PLGA10K-PEG5K, PLGA27K-PEG5K, PLGA45K-PEG5K, and PLGA95K-PEG5K (Boehringer
Ingelheim GmbH, Ingelheim, Germany and Akina Inc., West Lafayette, IN, USA) was
dissolved in acetonitrile (ACN, Sigma-Aldrich, St. Louis, MO, USA) at concentrations of
10–50 mg/mL. ACN and deionized water were employed as vertical and lateral sheath
streams, respectively. While NPs can be prepared using different organic solvents, ACN was
chosen because it is compatible with PDMS.29 The PLGA-PEG precursor in ACN was
introduced to the microchannel connected with the middle interconnecting holes. Pure ACN
was introduced to the microchannel connected with the first and the third interconnecting
holes. During the NPs synthesis, the flow rates were controlled by syringe pumps (Harvard
Apparatus, Holliston, MA, USA) and the device was observed using an inverted microscope
(Eclipse TS 100, Nikon, Tokyo, Japan). To confirm the vertical focusing, laser scanning
confocal microspcope (LSM 510, Carl Zeiss Microscopy, Göttingen, Germany) was used.
To obtain the confocal microscope images, aqueous solution of rhodamine 6G (Rh6G,
Sigma-Aldrich, St. Louis, MO, USA) and fluorescein isothiocyanate (FITC, Sigma-Aldrich,
St. Louis, MO, USA) were used as core and vertical sheath fluids, respectively. In case of
the bulk synthesis, 100 μL of polymeric precursor solution was mixed drop-wise with 1 mL
of water for about 2 h under magnetic stirring. The resulting NP suspensions were purified
by ultrafiltration using Amicon Ultracel 100 K membrane filters (EMD Millipore, Billerica,
MA, USA), washed three times with water, and resuspended in water or PBS.
Characterization of PLGA-PEG NPs
The size distribution by volume fraction of PLGA-PEG NPs was measured using dynamic
light scattering with Zetasizer Nano ZS (Malvern Instruments Ltd., Malvern, Worcs, UK).
The synthesized PLGA-PEG NPs were imaged by TEM (200CX, JEOL, Tokyo, Japan) with
negative staining by uranyl acetate (Electron Microscopy Sciences, Hatfield, PA, USA). For
the release study, we dialyzed docetaxel-loaded NPs in 20 L of PBS, pH 7.4, at 37 °C using
a 10 kDa cutoff membrane (Slide-A-Lyzer MINI Dialysis Devices, Thermo Scientific,
Rockford, IL, USA). The amount of docetaxel released from the NPs was measured by
HPLC (1100 Series, Agilent Technologies, Santa Clara, CA, USA).
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In vivo pharmacokinetics (PK) and biodistribution
All experiments were conducted as approved by the MIT Committee on Animal Care
(protocol #0710-055-13) and are in compliance with institutional and NIH guidelines. The
procedures for the in vivo PK experiments were adapted from a method reported
elsewhere.30–32 For the in vivo experiments, 5 wt% Alexa-fluor 647 (Life Technologies,
Grand Island, NY, USA) conjugated to PLGA45K (PLGA45K-A647) using 1-ethyl-3-(3-
dimethylaminopropyl)-carbo-diimide/N-hydroxysuccinimide chemistry was added to the
polymeric precursor. Male and female Balb/c mice weighting 25 g were intravenously dosed
with 5 mg of Alexa-fluor 647-labeled NPs via subclavian vein injection. At different time
intervals (5, 15, 30 min, and 1, 2, 4, 6 h) 50 μL of blood was sampled from the saphenous
vein using a heparinized hematocrit capillary tube. To minimize the amount of blood
removed on each animal, the different time-points were spread-out throughout the group to
ascertain that each mouse was not sampled more than 5 times. Twelve hours after injection,
a last blood sample was collected by cardiac puncture and the animals were euthanized by
cardiac perfusion of PBS under deep anesthesia. Tissues (heart, lung, liver, spleen, and
kidneys) were harvested for terminal biodistribution analysis (t = 12 h). Five animals were
used in each group.
All samples were maintained on ice until analyzed for fluorescent quantification of NPs in
plasma and organs (within 4 h). Blood samples were centrifuged at 2,000 rcf for 10 min, at 4
°C. The isolated plasma was collected and the volume was completed to 50 μL with mouse
plasma (Equitech-Bio, Kerrville, TX, USA). The fluorescence intensity was measured (λex:
650 nm, λem: 665 nm) on a 96-well plate-reader (Tecan, Männedorf, Switzerland) and
quantified using an 8-point calibration curve obtained from serial dilution in plasma of each
formulation. The limit of quantification (LOQ) was determined as the lowest concentration
for which the coefficient of variation in the calibration curve was below 10 % (19 μg/mL).
Samples with fluorescence below the LOQ were omitted. Moreover, to minimize the impact
of fluorescence quenching in concentrated samples, samples with concentrations above
1,250 μg/mL were further diluted until linearity in signal was achieved. The total
concentration in plasma at each time-point was obtained by multiplying the concentration of
each sample by the dilution factor used for preparation. The biodistribution data were
obtained from imaging the organs on an IVIS molecular imaging system (λex: 660 nm, λem:
680 nm). To account for the variability in the fluorescence of each formulation, the Total
Radiant Efficiency was normalized by the slope of each calibration curve.
PK data were treated by non-compartmental analysis of plasma concentration vs. time
profiles. Cmax corresponds to the maximum concentration measured while C0 is extrapolated
as the Y intercept of linear least-squares regression on the semilog plot of the plasma
concentration vs. time curve. Vd extrap is determined by dividing the injected dose by C0. The
apparent first-order terminal elimination rate (Kel) was estimated by linear least-squares
regression on the semilog plot of the plasma concentration vs. time curve. t1/2 is equal to ln2/
Kel. AUC0-t was calculated by the trapezoidal method from 0 to the last quantifiable time-
point. Areas under the blood concentration-time curve from time zero to infinity (AUC0-inf)
were calculated by adding AUC0-12 h to the ratio of the last measurable concentration to Kel.
Total Clearance was quantified as the injected dose divided by AUC0-inf.
Statistics were computed with SigmaPlot 11.0 software (Systat Software, Inc., San Jose, CA,
USA). Differences in group means were calculated by standard unpaired t test or Mann–
Whitney U test. The non-parametric tests were used if samples failed tests for equality of
variance and/or normality with the Kolmogorov-Smirnov test. A value of P < 0.05 was
considered significant. Table 1 lists which tests were used in each figure and table.
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Results
Design and fabrication of multilayer PDMS microfluidic device
The fabrication process for the parallel 3D HFF device is illustrated in Figure 1. The parallel
3D HFF devices were obtained by casting PDMS on a master mold fabricated in SU-8
photoresist using two-step lithography. The spin speed was tuned to precisely control the
PDMS thickness to be slightly lower than the interconnecting post height. The channel
width at the vertical focusing region and mixing region were 100 μm and 20 μm,
respectively. The height of upper and lower microchannels was fixed at 100 μm.
Figure 2, A shows a photograph of the parallel 3D HFF device, with isolated upper (red) and
lower (blue) layers filled with dye to highlight the geometries of the microchannels. Due to
the two-layer design, the device is simplified and can be interfaced with only 3 inlets and 1
outlet tubing (Figure 2, A). 3D HFF was achieved by three sequential interconnecting holes
for vertical focusing followed by a conventional cross junction for horizontal focusing.17
The organic phases (i.e., polymer solution in ACN and pure ACN) were supplied from upper
to lower layers through the three sequential interconnecting holes, visualized in Figure 2, B
using red and green food coloring dyes to represent the PLGA-PEG polymer in ACN
solution and pure ACN, respectively. The pure ACN streams focus the polymer stream
vertically to isolate it from the top and bottom walls to prevent channel fouling, while the
water stream focuses the organic streams horizontally to precipitate the NPs.17 The device
was designed with appropriate flow resistances to maintain an even distribution of flows to
the parallel channels (Figure 2, A and C).
Simulation and experimental visualization of vertical focusing
The vertical focusing 3D HFF with three sequential inlets is strongly affected by the shapes
of interconnecting holes. The effect of the geometry of the interconnecting holes on the
vertical focusing was examined by using 3D finite element simulations using COMSOL
(COMSOL Inc., Stockholm, Sweden) (Figure 3, A). Round interconnecting holes resulted in
non-uniform distribution of concentration profiles. Likewise, rectangular interconnecting
holes with lengths smaller than 100 μm resulted in arched vertical streams. The most
uniform concentration profiles were achieved when rectangular interconnecting holes with
lengths larger than 100 μm were used. Since larger SU-8 post arrays for replication of
interconnecting holes may hinder the uniformity of thin PDMS layer during the spin coating
process, the (streamwise) length of the interconnecting holes was fixed at 100 μm. To verify
the effect of the interconnect hole geometry, the performance of the multilayer 3D HFF
device was examined using confocal microscopy with aqueous Rh6G (red) and FITC
(green) fluorescent dye solutions as the polymer in ACN and ACN streams, respectively. As
predicted by the simulations, more uniform vertical focusing could be achieved using
rectangular interconnecting holes (100 μm × 120 μm) compared to circular holes (Figure 3,
B and C).17 The cross-section profiles and heights of the vertically focused streams obtained
by confocal microscopy were also in good agreement with the 3D finite element simulations
at various fractions of polymer flow in organic flow (f) (Figure 3, D and E).
Preparation and characterization of PLGA-PEG NPs
PLGA-PEG NPs with a range of sizes from 13 nm to 150 nm were prepared using the
parallel 3D HFF device, demonstrating its utility for the synthesis of NPs with precise
control over the particle size. To accomplish this size control, we varied both the PLGA
block lengths (10, 27, 45, and 95 kDa) and polymer concentration in ACN (10–50 mg/mL)
(Figure 4, A). For some conditions 2D HFF and the bulk synthesis method yielded
polydisperse particles due to the aggregation of the polymeric precursor, whereas 3D HFF
provided more homogeneous NPs. Figure 4, B shows the size distributions by volume
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fraction of NPs synthesized from PLGA45K-PEG5K precursor at high concentrations (50 mg/
mL) using the three different methods (i.e., 3D HFF, 2D HFF, and bulk synthesis method).
Here, the f of 3D HFF and 2D HFF were 0.7 and 1, respectively. Next, we; compared NPs
prepared using the 8 parallel stream 3D HFF device to a single stream 3D HFF device
fabricated in a similar manner. We observed that the size of NPs prepared with the single
and 8 parallel 3D HFF was essentially identical within standard error (Figure 4, C). The size
of NPs can be controlled simply by changing the flow ratio of polymer stream to the total
flow rate of water (R).13,33 When PLGA10K-PEG5K at high concentration (50 mg/mL) is
used, the size drops from 26 nm to 13 nm as the R decreased from 0.2 to 0.02 (Figure 4, D).
Similarly, NPs size decreased from 40 nm to 20 nm as the R decreased when PLGA27K-
PEG5K at high concentration (50 mg/mL) is used (Figure 4, E). To further assess to potential
of the platform for drug delivery purposes, we assembled drug-encapsulating NPs by bulk
synthesis and parallel 3D HFF using PLGA10K-PEG5K as the polymeric precursor and
docetaxel as a model therapeutic agent. In both cases, the NPs behaved similarly with 50 %
of the drug release achieved after 5 h (Figure 4, F).
Proof-of-concept in vivo PK and biodistribution of small NPs
As a proof of concept, we utilized the microfluidic platform to study the biological behavior
of NPs with two different sizes prepared by controlling the mixing time. In vivo PK and bio-
distribution were examined using Alexa-fluor 647 to label the NPs synthesized by the 8
parallel 3D HFF. Because Alexa-fluor 647 conjugated PLGA45K (PLGA45K-A647) was
added to the PLGA10K-PEG5K precursor (5 wt%), the diameter of Alexa-fluor 647-labeled
NPs was slightly increased compared to unlabelled NPs. At R = 0.04 and 0.2, the average
diameters of Alexa-fluor 647-labeled NPs were 20 nm and 35 nm, respectively.
Interestingly, these NPs showed similar behavior when injected intravenously to mice
without significant differences in circulation profiles and PK parameters (Figure 5, A and
Table 1). Similarly, terminal distribution of the fluorescence in organs of the mononuclear
phagocyte system (i.e., liver, spleen, and lungs)32 as well as the fluorescence in the kidneys
and heart were comparable for both NPs (Figure 5, B).
Discussion
We demonstrated the parallelization of microchannels to increase production yield without
impairing reproducibility, controllability, and robustness of microfluidic synthesis of NPs. In
principle, the parallelization strategy could expand to clinically relevant production rates.9
Recently, fabrication of parallelized PDMS microfluidic devices was demonstrated,23,24,26
but manual drilling or punching that provide limited accuracy and repeatability between
devices were used to fabricate the interconnecting holes. In 3D HFF with three sequential
inlets, the lateral position of the inlet holes significantly affects the vertical focusing, which
is difficult to control by manual drilling.17 Instead, we defined the interconnecting holes in
the parallel 3D HFF device by patterned SU-8 posts, which allowed for optimization of their
cross-sectional geometry and excellent alignment with the microchannels. This approach
reduced the manual interventions during the manufacturing process and resulted in lower
variability of the chip-to-chip performance.34
The flow conditions of each 3D HFF unit in the 8 parallel 3D HFF device are designed to be
the same as those in a single 3D HFF channel device. Therefore, the size of NPs prepared
with the single and 8 parallel 3D HFF was essentially identical within standard error (Figure
4, C). In contrast, we observed a large difference between the 3D HFF and bulk synthesis
(Figure 4, C). To achieve the same flow conditions in each 3D HFF unit in the 8 parallel 3D
HFF device, the flow resistance in each channel should be precisely regulated. Since the
flow resistance for laminar flow through a channel is proportional to the length of channel,
Lim et al. Page 6
Nanomedicine. Author manuscript; available in PMC 2015 February 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
the microchannels were branched symmetrically to balance the flow resistances. In addition,
the microchannel for the top sheath stream was meandered to balance the flow resistances
(Figure 2, C). The upper and lower layers are separated by a PDMS membrane, but the
pressure in the lower layer is much larger than that of upper layer. As a result, the PDMS
membrane protrudes into the upper microchannels where the upper and lower microchannels
cross, increasing the resistance of upper microchannel. The resistance increase is higher
when the area of channel overlap region is larger. Since PDMS made of 4:1 base to hardener
mixture is stiffer, 4:1 base to hardener mixture was used to minimize the protrusion of the
PDMS membrane. In addition, the microchannels were branched off at the overlapping
region to distribute the effect of resistance increase evenly. Since the parallel channels are
coupled to each other, dust or aggregates of PLGA-PEG impede an even distribution of flow
to the parallel channels. Square PDMS posts, which could filter out the dusts and aggregates,
were therefore placed around the interconnecting holes (Figure 2, B and C).
Parallel 3D HFF devices were obtained by casting PDMS on a master mold fabricated in
SU-8 photoresist using two-step lithography. Since the interconnecting holes between upper
and lower PDMS channels were defined by patterned SU-8 posts, their shape could be
optimized and excellent alignment of the holes and channels could be achieved. Because of
the optimal shape and excellent alignment of interconnecting holes, the vertically focused
stream did not touch the PDMS microchannels even at high f (f = 0.7). Therefore, NPs with
uniform size distribution could be synthesized consistently in case of 3D HFF. However, 2D
HFF and the bulk synthesis method yielded poly-disperse particles due to the aggregation of
polymeric precursors in some cases.
Considering that the pure ACN sheath flows do not contain any NP precursors, this
configuration allows us to maintain the yield of NPs while enabling robust operation of the
system (Table 2). Minimal dilution of the precursor solution by pure ACN allowed the
production rate of NPs to increase to 84 mg/h when 8 parallel 3D HFF was operated at high
f (f = 0.7). This increase in yield shortens the preparation time for batches of NPs suitable for
a series of in vivo mice experiments (25 mg) from over 5 h17 to less than 20 minutes, which
is critical to minimize drug release during NP synthesis. Furthermore, the NP production
rate could be increased further by increasing the flow ratio as well as by increasing the
number of parallel microchannels.
Many different organic solvents including tetrahydrofuran, acetone, and dimethylformamide
have been used for conventional bulk NP preparation.5 However, PDMS tends to swell in
presence of many organic solvents, which would alter the fluid dynamics in the PDMS
device. We used ACN and water for NP preparation because they are compatible with
PDMS.29 Other organic solvents including nitromethane, dimethyl sulfoxide, ethylene
glycol, perfluorotributylamine, perfluorodecalin, and propylene carbonate can potentially be
adopted for NP synthesis using our system as they do not swell PDMS.29
Since the size of NPs is one of the key factors that determine the biodistribution and
therapeutic efficacy,3,8,32,35 the ability to tune NPs size is important. We further established
the potential of this platform by reproducibly synthesizing NPs with sizes tunable between
13 and 150 nm. Self-assembly of NPs under conditions of the most rapid mixing with lowest
MW PLGA block (10 kDa) resulted in the smallest NPs (~13 nm diameter), which is very
difficult to achieve with bulk synthesis methods. Similarly the highest MW PLGA block (95
kDa) and high polymer concentration resulted in the largest NP sizes (~150 nm diameter).
Interestingly, all NPs had consistent average size batch-to-batch, and uniform size
distribution.
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In HFF devices, for fixed MW and concentration of polymeric precursor, the size of the NPs
strongly depends on the mixing time (τmix), which can be estimated by equation (1).13,33
(1)
Where D is diffusivity of the solvent, wf is width of the focused stream, w is channel width,
and R is the ratio of flow rate of the organic stream to the total flow rate of water. NPs
obtained using the microfluidic channels are smaller than those synthesized from the bulk
synthesis method because the τmix is smaller than the characteristic aggregation time scale
(τagg) (Figure 4, D and E).13 In the current devices, Eq. (1) predicts τmix in the range of
0.017–1.2 ms for typical flow ratios (R = 0.02–0.2). The influence of τmix on the size of NPs
disappears when τmix is smaller than 0.066 ms (R = 0.04), suggesting that these NPs have
reached the size limit for this specific copolymer.33
The ability to reproducibly synthesize small and monodisperse NPs exhibiting similar fate in
vivo is particularly appealing in light of the recent literature reporting enhanced penetration
of smaller NPs into solid tumors.36,37 If NPs of two different sizes exhibit similar PK, we
may expect the smaller NPs to be more effectively penetrate into solid tumors. Microfluidic
platforms are advantageous for synthesis of small NPs by nanoprecipitation due to their
ability to rapidly mix the precursors; NPs prepared by bulk nanoprecipitation tend to be
larger.13,17,33 A recent paper reported a different parallel flow focusing system that resulted
in smaller NPs, although in vivo studies were not performed and the NP size was 50 – 200
nm.38
While is relatively simple to synthesize sub-30 nm inorganic NPs at large scales, it has
remained challenging to synthesize polymeric NPs in this size range, especially loaded with
drug and with controlled release properties. The parallel 3D HFF device enables the
synthesis of small NPs with high production rates that allowed for in vivo studies. Since
smaller NPs can penetrate more deeply into solid tumors,36,37 parallel microfluidic synthesis
has the potential to lead to the development of improved NPs with better drug delivery
performance compared to larger NPs obtained by bulk synthesis. Therefore, the use of the
parallel 3D HFF device to synthesize a variety of such NPs would likely prove a very
valuable tool in the pre-clinical in vivo screening of these materials for cancer therapy.
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Figure 1.
3D Schematic illustration of fabrication procedure for the multilayer 3D HFF device. For
clarity, the single channel 3D HFF device is depicted.
Lim et al. Page 11
Nanomedicine. Author manuscript; available in PMC 2015 February 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
3D HFF microfluidic device for parallel NP synthesis. (A) Device visualized using red and
blue food coloring dyes in the upper and lower microchannels, respectively. PDMS was
spin-coated thicker than the SU-8 post arrays (i.e., interconnecting holes were closed) to
isolate the channels. (B) Optical microscope image of the 3D HFF region. Here, red and
green food coloring dyes represent the PLGA-PEG polymer in ACN solution and pure
ACN, respectively. (C) Schematic illustration of one of the 8 parallel 3D HFF units in the
device.
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Figure 3.
Vertical focusing in the 3D HFF device (Re = 0.833). Both width and height of the lower
microchannel are 100 μm. (A) Perspective views of 3D finite element simulations at the
vertical focusing region with round (120 μm in diameter), rectangular (50 μm × 120 μm),
rectangular (100 μm × 120 μm), and square (120 μm × 120 μm) shapes of interconnecting
holes. Here, the fraction of polymer flow in organic flow (f) is 0.3. (B) Cross-sectional side
view and (C) cross-sectional front view of confocal microscopy images at the vertical
focusing region when the fraction of polymer flow in organic flow (f) is 0.3. Width and
length of interconnecting holes are 120 μm and 100 μm, respectively. Fluid flows in the x-
direction after focusing. (D) Height of vertically focused polymeric stream as a function of f.
(E) Cross-sectional side view from the 3D finite element simulation and confocal
microscope images at the vertical focusing region as a function of f.
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Figure 4.
NP synthesis and drug release. (A) Effect of PLGA-PEG precursor concentrations on the
size of synthesized PLGA-PEG NPs depending on the MW of polymeric precursors (f = 0.7,
R = 0.1). (B) The size distribution by volume fraction of NPs prepared from PLGA45K-
PEG5K by microfluidic 3D HFF at (f = 0.7, R = 0.1), 2D HFF (f = 1, R = 0.1), and bulk
synthesis method. Here, the precursor concentration was 50 mg/mL. (C) The size
distribution by volume fraction of NPs prepared from 10 mg/mL PLGA10K-PEG5K by single
3D HFF, 8 parallel 3D HFF, and bulk synthesis (f = 0.7, R = 0.04). (D, E) Effect of flow
ratio on NPs size prepared from (D) PLGA10K-PEG5K and (E) PLGA27K-PEG5K by 3D
HFF at f = 0.7. NPs prepared by 3D HFF were smaller in size than those obtained by bulk
synthesis. The inset shows TEM image of the NPs prepared by 3D HFF (f = 0.7, R = 0.04).
Scale bar is 100 nm. (F) Docetaxel release profile of NPs prepared from 50 mg/mL
PLGA10K-PEG5K by 3D HFF and bulk synthesis.
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Figure 5.
PK and biodistribution in mice of small NPs synthesized by 3D HFF. (A) The systemic
circulation lifetime of Alexa-fluor 647-labeled PLGA10K-PEG5K NPs prepared with two
different flow ratios to tune the size (R = 0.04 and 0.2 for 20 nm and 35 nm diameters,
respectively). (B) The fluorescence intensity per organ of Alexa-fluor 647-labeled NPs at 12
h from intravenous injection. Five animals were used in each group. Both NPs showed
similar behavior when injected intravenously to mice without significant differences in
circulation profiles, PK parameters, and terminal distribution of the fluorescence in organs.
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Table 1
The summary of calculated PK parameters, P values, and statistical test methods.
20 nm NPs 35 nm NPs P value Statistical test
Half-life (h) 1.3 ± 0.19 1.7 ± 0.30 p = 0.095 Mann–Whitney
Ke (h−1) 0.5 ± 0.09 0.4 ± 0.09 p = 0.095 Mann–Whitney
AUC0-12h (%ID.h.mL−1) 168 ± 56 156 ± 61 p = 0.371 t-test
AUC0-inf (%ID.h.mL−1) 169 ± 56 157 ± 62 p = 0.378 t-test
Vd extrap (mL) 1.2 ± 0.50 2.0 ± 0.83 p = 0.055 t-test
Vd area (mL) 1.3 ± 0.84 1.8 ± 0.74 p = 0.186 t-test
Clearance (mL/h) 0.7 ± 0.37 0.7 ± 0.23 p = 0.461 t-test
Cmax (%ID.mL−1) 81 ± 25 72 ± 27 p = 0.301 t-test
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Table 2
The production rate of NPs and time required for synthesis of 25 mg of NPs for single flow focusing and 8
parallel flow focusing, respectively. Here, the flow ratio were fixed at R = 0.1.
Single 3D HFF (f = 0.3)17 Single 3D HFF (f = 0.7) 8 3D HFF (f = 0.7)
Flow rate of polymeric precursor 1.5 μL/min 3.5 μL/min 28 μL/min
Flow rate of water 50 μL/min 50 μL/min 400 μL/min
Polymer concentration 50 mg/mL 50 mg/mL 50 mg/mL
Production rate 4.5 mg/h 10.5 mg/h 84 mg/h
Time for 25 mg NPs 334 min 143 min 18 min
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